December 9
QLT Announces 2003 Analyst & Investor Meeting and Webcast
PDF version
November 17
QLT Provides Update on American Academy of Ophthalmology Meeting
November 6
QLT Files Form S-3 for its August 2003 Private Placement of Convertible Notes
October 23
QLT Announces Q3 Results for 2003 and Updates Guidance
October 20
QLT Announces Visudyne® Sales for the Third Quarter of 2003
October 16
Visudyne® Approved in Japan for Treatment of Age-related Macular Degeneration (AMD)
September 18
QLT Announces the Completion of Development Milestones in its Continued Efforts to Expand the Availability of Visudyne� in Wet AMD Market
September 9
QLT Announces Favorable Vote from Medicare Panel to Support Visudyne� Therapy for Use in Occult Patients
August 15
QLT Announces Closing of US $172.5 Million U.S. Private Convertible Senior Note Financing
August 13
QLT Announces Exercise of Option to Acquire Additional US$22.5 Million Senior Convertible Notes
August 12
Boyd Clarke Joins QLT's Board of Directors
August 11
QLT Announces Terms of US $150 Million U.S. Private Convertible Senior Notes Offering
QLT Announces TSX Approval of US $50 Million Share Repurchase Program
QLT Announces Proposed US $50 Million Share Repurchase Program
QLT Announces Proposed US $150 Million U.S. Private Convertible Senior Notes Offering
July 23
QLT Announces Q2 Results for 2003 and Updates Guidance
July 21
QLT Announces Visudyne® Sales for Second Quarter of 2003
May 12
QLT Discontinues Tariquidar Phase III Non-Small Cell Lung Cancer Trials Following Planned Interim Analysis By The Independent Data Safety Monitoring Committee
May 6
Visudyne® Receives Prestigious Award for Innovation in Eye Care
New Clinical Data Confirm Role of Visudyne� (verteporfin) Therapy as Standard of Care in Choroidal Neovascularization (CNV) due to Age-Related Macular Degeneration
April 24
QLT Announces Q1 Results for 2003 and Updates Guidance
April 15
QLT Announces Visudyne� Sales for First Quarter of 2003
March 28
QLT Announces Change in Reporting to U.S. GAAP and the U.S. Dollar from Canadian GAAP and the Canadian Dollar
February 21
QLT Temporarily Suspends New Patient Accrual in Phase III Studies of Tariquidar Pending Planned Interim Analysis
February 5
QLT Reports 2002 Fourth Quarter and Full-Year Earnings Per Share, Excluding Special Charges, of $0.16 and $0.47 and Provides Guidance for 2003
January 23
QLT Announces Visudyne� Sales for Fourth Quarter and Fiscal Year 2002
January 6
QLT to Participate in JP Morgan H&Q Healthcare Conference
